Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.

Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.